Who
Franziska Michor
Director
Company insider
Files Form 4 as: Director, Recursion Pharmaceuticals.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 20 Nov 2024
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,031 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —22,016 at $0.00 | filing |
| 20 Nov 2024filed 22 Nov 2024 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,670 | filing |
| 20 Nov 2024filed 22 Nov 2024 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,286 | filing |
| 20 Nov 2024filed 22 Nov 2024 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,694 | filing |
| 20 Nov 2024filed 22 Nov 2024 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —82,781 at $0.00 | filing |
| 20 Nov 2024filed 22 Nov 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,618 | filing |
| 20 Nov 2024filed 22 Nov 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,335 at $0.00 | filing |
| 20 Nov 2024filed 22 Nov 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —17,694 at $0.00 | filing |
| 20 Nov 2024filed 22 Nov 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —41,390 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.